<DOC>
	<DOCNO>NCT01689220</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability SP-02L monotherapy Korean patient relapse refractory Peripheral T-cell Lymphoma ( PTCL ) .</brief_summary>
	<brief_title>A Phase 1 Study SP-02L Relapsed Refractory Patients With Peripheral T-cell Lymphoma ( PTCL ) Korea</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>Korean patient age â‰¥ 20 year age day obtain informed consent Patients histologically confirm diagnosis follow : PTCL , otherwise specify ( PTCLNOS ) Anaplastic Large Cell Lymphoma ( ALCL ALKpositive/negative ) Angioimmunoblastic Tcell Lymphoma ( AITL ) Have relapse refractory least one prior systemic chemotherapy disease ( currently require therapy ) Have least 1 evaluable lesion Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy least 3 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>